Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc.

OOTC:KBLB
0.08
USD
+0.00
(-0.52%)
0.00EPS
113.40MMarket Cap

Total Valuation

USD

As of June 30, 2026, Kraig Biocraft Laboratories, Inc. carries a market capitalization of 113.40M, placing it among publicly traded companies globally. Its enterprise value stands at 116.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap113.40M
Enterprise Value116.93M

Share Statistics

As of June 30, 2026, Kraig Biocraft Laboratories, Inc. has 1.11B shares outstanding.

Shares Outstanding1.11B

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio-9.46
P/TBV Ratio-9.46
P/FCF Ratio-53.20
P/OCF Ratio-54.36

Financial Position

As of June 30, 2026, Kraig Biocraft Laboratories, Inc. maintains a current ratio of 0.33, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -24.97, indicating conservative leverage, while an interest coverage ratio of -6.22 demonstrates limited ability to service its debt obligations.

Current Ratio0.33
Quick Ratio0.31
Debt / Equity-24.97
Debt / EBITDA-0.46
Interest Coverage-6.22

Financial Efficiency

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -141.54, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 21.50, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-141.54
Employee Count21.50

Stock Price Statistics

USD

As of the close on November 16, 2026, Kraig Biocraft Laboratories, Inc.'s stock has declined approximately 3.04% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.11.

52-Week Price Change-3.04%
50-Day Moving Average0.08
200-Day Moving Average0.11

Income Statement

USD

Over the twelve months ended June 30, 2026, Kraig Biocraft Laboratories, Inc. generated - - in revenue and converted that into -4.15M in net income, yielding earnings per share of 0.00. EBITDA reached -3.66M, while operating income came in at -3.69M.

Operating Income-3.69M
Pretax Income-4.15M
Net Income-4.15M
EBITDA-3.66M
EBIT-3.69M

Balance Sheet

USD

As of June 30, 2026, Kraig Biocraft Laboratories, Inc. holds 3.39M in cash and equivalents against 1.69M in total debt, resulting in a net debt position of -1.90M. Total book value stands at -11.99M, with working capital of -7.33M providing operational flexibility.

Cash & Cash Equivalents3.39M
Total Debt1.69M
Net Debt-1.90M
Equity (Book Value)-11.99M
Book Value Per Share-0.01
Working Capital-7.33M

Cash Flow

USD

Kraig Biocraft Laboratories, Inc. produced -2.04M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -44,336.00 in capital expenditures, free cash flow totaled -2.08M - equivalent to 0.00 per share.

Operating Cash Flow-2.04M
Capital Expenditures-44,336.00
Free Cash Flow-2.08M

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.88: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.87, meaning Kraig Biocraft Laboratories, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-3.87
FCF Yield-1.88

Stock Splits

Kraig Biocraft Laboratories, Inc.'s most recent stock split took place on May 28, 2009 with a 1:10 split ratio.

Last Split Date5/28/2009
Split Ratio1:10

Scores

As of June 30, 2026, Kraig Biocraft Laboratories, Inc. has an Altman Z-Score of -17.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-17.93